Roth Capital Starts Cempra, Inc. (CEMP) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/1/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Short sellers pile into SpaceX ahead of earnings, lockup expiration
- Wall Street ends higher as Amazon soothes AI jitters
- Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Cempra (CEMP) to Offer $100M in Stock
January 5, 2015 4:04 PM ESTCempra, Inc. (Nasdaq: CEMP) announced its intention to offer and sell shares of its common stock with an aggregate public offering price of approximately $100 million in an underwritten public offering pursuant to its existing shelf registration statement. The company also intends to... More
Cempra (CEMP) Surges on Positive Phase 3 Results for Solitaire-Oral
January 5, 2015 7:08 AM ESTCempra (NASDAQ: CEMP) is sharply higher (+29%) in pre-open trading Monday after the company announced positive topline results from a global, pivotal Phase 3 clinical trial of solithromycin oral capsules (Solitaire-Oral) in the treatment of patients with community acquired bacterial pneumonia (CABP).
In the intent-to-treat population (ITT, all randomized patients), solithromycin met the primary objective of statistical non-inferiority (10% non-inferiority margin) of the early clinical response at 72 (-12/+36) hours after initiation of therapy compared to moxifloxacin. Solithromycin also met the secondary objectives of... More
Cempra (CEMP) PT Raised to $32 at Baird on Positive Solithromycin Data
January 5, 2015 6:27 AM ESTBaird analyst Brian Skorney reiterated an Outperform rating and boosted his price target on Cempra, Inc. (NASDAQ: CEMP) to $32.00 (from $21.00) after Solithromycin clears first phase 3 hurdle.
"We're encouraged by the top-line results posted by Cempra from its Solitaire-Oral study featuring solithromycin,"... More
